StratifAI, the AI precision oncology company behind the Polaris™ platform, today announced its selection for the ...

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.

Is Social Isolation an Overlooked Risk Factor in Cancer Mortality? People with cancer who experience loneliness or social ...

I went into cancer care and cancer research because, when I was a fellow, it was the medical specialty with the largest ...

More Than Half of Cancers Detected by Galleri Were Early Stage Approximately Three-Quarters of Galleri-Detected Cancers Do Not Have Recommended Screenings ...

The Singapore-based parent company of Optus has come under heavy scrutiny after another Australian network outage prevented hundreds of customers from accessing the triple-0 emergency service.

Key financial data from the Company’s filing on June 30 ... Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that ...

The five-year invasive disease-free survival (iDFS) rates were 85.5% in the Kisqali plus ET arm versus 81.0% in the ET alone arm, representing a clinically meaningful 4.5% improvement 1. These ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated, commercial biotechnology ...